Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies

Detalles Bibliográficos
Autores principales: Kobayashi, Roger H., Gupta, Sudhir, Melamed, Isaac, Mandujano, J. Fernando, Kobayashi, Ai Lan, Ritchie, Bruce, Geng, Bob, Atkinson, Thomas Prescott, Rehman, Syed, Turpel-Kantor, Eva, Litzman, Jiří
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809273/
https://www.ncbi.nlm.nih.gov/pubmed/36605207
http://dx.doi.org/10.3389/fimmu.2022.1110388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809273/
https://www.ncbi.nlm.nih.gov/pubmed/36605207
http://dx.doi.org/10.3389/fimmu.2022.1110388

Ejemplares similares